Quoin Pharmaceuticals, Ltd. QNRX
Regular-session close
Pre-market · Nov 16, 8:33 AM ET
- YTD
- -74.36%
- 1 year
- -72.43%
- Market cap
- 17.78M
- EPS (ttm)
- 0.44
- Shares out
- 5.05M
- P/E ratio
- 8.41
- Forward P/E
- -0.43
- YTD return
- -74.36%
- 1-year return
- -72.43%
- 50-day average
- 0.69104
- 200-day average
- 0.6863
- Volume
- 16.03K
- Avg volume
- 542.37K
- Open
- 3.99
- Previous close
- 3.70
- Day's range
- 3.55 – 3.99
- 52-week range
- 3.25 – 23.50
- Beta
- 1.89
- Analysts
- Strong Buy
- Price target
- 4.50 (+21.6%)
5D -0.05 (-1.31%)
Key statistics
- Enterprise value
- -6.59M
- Price / book
- 0.09
- Free cash flow
- -5.05M
- Total cash
- 12.57M
- Total debt
- 3.22M
- Return on equity
- -100.03%
- Short % of float
- 0.48%
Fundamental scorecard
6 of 25 checks passed on QNRX’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth No data
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.44 | -0.47 | -0.03 | -6.82% |
| Aug 8, 2024 | Jun 1, 2024 | -0.75 | -0.39 | +0.36 | +48.00% |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.11 | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -2.37 | -2.08 | +0.29 | +12.24% |
| Nov 8, 2023 | Sep 1, 2023 | -2.40 | -1.95 | +0.45 | +18.75% |
| Aug 2, 2023 | Jun 1, 2023 | 0.00 | -2.13 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 15, 2024 | Maxim Group | main | Buy | Buy |
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- quoinpharma.com
News
Quoin Pharmaceuticals Q3 EPS $(0.97) Beats $(1.52) Estimate
12 Health Care Stocks Moving In Monday's After-Market Session Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18
Your note
Sign in to keep a note on QNRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER DENISE P | Chief Operating Officer | Purchase | Sep 3, 2024 | 47,092 |
| DUNN GORDON | Chief Financial Officer | Purchase | Sep 9, 2024 | 28,856 |
| MYERS MICHAEL | Chief Executive Officer | Purchase | Sep 3, 2024 | 47,252 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.77% | 38,691 | 20.20K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.63% | 31,854 | 16.63K | Sep 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 0.50% | 25,119 | 13.11K | Sep 29, 2024 |
| Virtu Financial LLC | 0.50% | 25,165 | 13.14K | Sep 29, 2024 |
| UBS Group AG | 0.45% | 22,821 | 11.91K | Sep 29, 2024 |
| Rhumbline Advisers | 0.41% | 20,786 | 10.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 95 | 49 | Apr 29, 2024 |
